- Home
- HIVE vs CDXC Comparison
HIVE vs CDXC Comparison
Compare HIVE & CDXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HIVE
- CDXC
- Stock Information
- Founded
- HIVE 1987
- CDXC 1999
- Country
- HIVE Canada
- CDXC United States
- Employees
- HIVE N/A
- CDXC N/A
- Industry
- HIVE
- CDXC Medicinal Chemicals and Botanical Products
- Sector
- HIVE
- CDXC Health Care
- Exchange
- HIVE Nasdaq
- CDXC Nasdaq
- Market Cap
- HIVE 527.8M
- CDXC 449.5M
- IPO Year
- HIVE N/A
- CDXC N/A
- Fundamental
- Price
- HIVE $2.91
- CDXC $5.51
- Analyst Decision
- HIVE Strong Buy
- CDXC Strong Buy
- Analyst Count
- HIVE 6
- CDXC 2
- Target Price
- HIVE $7.42
- CDXC $8.00
- AVG Volume (30 Days)
- HIVE 11.0M
- CDXC 341.1K
- Earning Date
- HIVE 02-11-2025
- CDXC 03-05-2025
- Dividend Yield
- HIVE N/A
- CDXC N/A
- EPS Growth
- HIVE N/A
- CDXC N/A
- EPS
- HIVE N/A
- CDXC 0.02
- Revenue
- HIVE $123,022,000.00
- CDXC $91,668,000.00
- Revenue This Year
- HIVE N/A
- CDXC $18.64
- Revenue Next Year
- HIVE $90.65
- CDXC $20.72
- P/E Ratio
- HIVE N/A
- CDXC $280.54
- Revenue Growth
- HIVE 55.97
- CDXC 9.95
- 52 Week Low
- HIVE $2.18
- CDXC $1.46
- 52 Week High
- HIVE $5.54
- CDXC $7.97
- Technical
- Relative Strength Index (RSI)
- HIVE 42.32
- CDXC 41.29
- Support Level
- HIVE $2.69
- CDXC $5.45
- Resistance Level
- HIVE $3.17
- CDXC $6.08
- Average True Range (ATR)
- HIVE 0.22
- CDXC 0.28
- MACD
- HIVE 0.01
- CDXC -0.01
- Stochastic Oscillator
- HIVE 32.89
- CDXC 3.75
About HIVE HIVE Digital Technologies Ltd.
HIVE Digital Technologies Ltd is in the business of providing infrastructure solutions in the blockchain industry. It focuses on the mining and sale of digital currencies. Its geographical segments include Canada, Sweden, Iceland, Switzerland, and Bermuda, out of which the majority of the revenue comes from Bermuda.
About CDXC ChromaDex Corporation
ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segments namely Consumer Products, Ingredients segment, and Analytical Reference Standards and Services. The majority of the revenue is earned from the Consumer Products segment.